This page has only limited features, please log in for full access.
The ability of the immune system to precisely target and eliminate aberrant or infected cells has long been studied in the field of infectious diseases. Attempts to define and exploit these potent immunological processes in the fight against cancer has been a longstanding effort dating back over 100 years to when Dr. William Coley purposefully infected cancer patients with a cocktail of heat-killed bacteria to stimulate anti-cancer immune processes. Although the field of cancer immunotherapy has been dotted with skepticism at times, the success of immune checkpoint inhibitors and recent FDA approvals of autologous cell therapies have pivoted immunotherapy to center stage as one of the most promising strategies to treat cancer. This review aims to summarize historic milestones throughout the field of cancer immunotherapy as well as highlight current and promising immunotherapies in development.
Robert D. Carlson; Jr. John C. Flickinger; Adam E. Snook; John Jr. Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy. Toxins 2020, 12, 241 .
AMA StyleRobert D. Carlson, Jr. John C. Flickinger, Adam E. Snook, John Jr. Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy. Toxins. 2020; 12 (4):241.
Chicago/Turabian StyleRobert D. Carlson; Jr. John C. Flickinger; Adam E. Snook; John Jr. 2020. "Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy." Toxins 12, no. 4: 241.
Listeria monocytogenes, a Gram-positive facultative anaerobic bacterium, is becoming a popular vector for cancer immunotherapy. Indeed, multiple vaccines have been developed utilizing modified Listeria as a tool for generating immune responses against a variety of cancers. Moreover, over a dozen clinical trials testing Listeria cancer vaccines are currently underway, which will help to understand the utility of Listeria vaccines in cancer immunotherapy. This review aims to summarize current views on how Listeria-based vaccines induce potent antitumor immunity and the current state of Listeria-based cancer vaccines in clinical trials.
Jr. John C. Flickinger; Ulrich Rodeck; Adam E. Snook. Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress. Vaccines 2018, 6, 48 .
AMA StyleJr. John C. Flickinger, Ulrich Rodeck, Adam E. Snook. Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress. Vaccines. 2018; 6 (3):48.
Chicago/Turabian StyleJr. John C. Flickinger; Ulrich Rodeck; Adam E. Snook. 2018. "Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress." Vaccines 6, no. 3: 48.